Takeda's New CEO Files to Sell $1.6M in ADSs from Vested RSUs
TAK sits 26% above its 52-week low of $12.99.
Summary
Takeda's new CEO Julie Kim filed to sell 96,558 ADSs worth ~$1.62 million from recently vested RSUs, a notable move given her recent appointment and the company's ongoing legal and financial headwinds.
Key Events · Ownership and Investor Activity · TAK
-
CEO Files to Sell $1.6M in ADSs
President and CEO Julie Kim filed a Form 144 to sell 96,558 ADSs acquired via RSU vesting on July 1, 2026, with an approximate market value of $1,617,344.29.
-
Sale Follows Recent RSU Vesting
The shares were acquired as compensation through restricted stock unit awards that vested on July 1, 2026; the sale likely covers tax obligations or personal diversification.
-
CEO Appointment and Company Challenges
Kim was officially appointed CEO on June 24, 2026, amid a period of significant legal and financial strain, including a $2.5 billion antitrust provision and a FY2026 net loss.
-
No Prior Sales in Past 3 Months
The filing indicates no other sales by Kim in the past three months, making this her first reported disposition as CEO.
Analysis · TAK · Life Sciences
Just weeks into her tenure, Takeda's newly appointed CEO Julie Kim has filed a Form 144 to sell 96,558 American Depositary Shares (ADSs) acquired through restricted stock unit (RSU) vesting on July 1, 2026. The proposed sale, valued at approximately $1.62 million based on recent prices, is likely tied to tax planning or diversification following the vesting event. Still, it lands during a turbulent stretch for the company, which recently booked a $2.5 billion litigation provision and reported a net loss for FY2026. While the amount is modest relative to Takeda's $52.9 billion market cap, the market may interpret the CEO's sale as a signal of near-term caution.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TAK was trading at $16.37 on NYSE in the Life Sciences sector, with a market capitalization of approximately $52.9B. The 52-week trading range was $12.99 to $18.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.